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 ABSTRACT 
 
Introduction: KwaZulu-Natal has a high burden of HIV infection and high blood pressure, specifically 
pre-eclampsia (PE) in pregnancy. Follistatin (FS) and granulocyte-colony stimulating factor (G-CSF) 
are two glycoproteins involved in PE pathogenesis. FS is an extracellular glycoprotein antagonist of the 
ligand receptor, activin. G-CSF on the other hand drives the generation of neutrophilic granulocytes 
from myeloic precursor cells by its inhibition of apoptosis and induction of differentiation. In light of 
the high maternal mortality and morbidity in South Africa (SA), we investigated the expression of FS 
and G-CSF in the duality of HIV-associated PE.  
Method: Serum samples of normotensive and pre-eclamptic women further stratified by HIV status 
were collected from a large regional hospital in Durban, and their FS and G-CSF expression was 
analysed using the Bio-Plex Multiplex Immunoassay.  
Results: FS expression was significantly reduced in pre-eclamptic compared to normotensive 
pregnancies (649.5±116.8 vs 2354±353.6; p<0.001). However, FS expression did not differ between 
HIV +ve vs HIV –ve groups (1727±291.2 vs 1305±306.7; p=0.13). Furthermore, we detected significant 
FS expression across all study groups. The expression of G-CSF was not affected by HIV status i.e., 
between HIV +ve vs HIV -ve groups (14.4±2.3 vs 11.6±0.7, p=0.10) and there was no significant 
difference in the expression of G-CSF between normotensive vs pre-eclamptic (14.9±2.4 vs 11.3±0.5, 
p=0.32). G-CSF expression was notably higher in HIV +ve normotensive when compared to all study 
groups. 
Conclusion: This study demonstrates a downregulation of FS and G-CSF expression in PE, compared 
to normotensive pregnancies. This finding may be attributed to oxidative stress and its immuno-
regulatory role in the hyper-inflammatory milieu of PE. In addition, the downregulation of both analytes 
may be attributed to the anti-angiogenic micro-environment of PE. HIV status probably had no effect 
on both analytes albeit, upregulated due to immune reconstitution emanating from HAART. Our novel 
findings suggest that FS and G-CSF may have a potential predictor test value in early pregnancy, hence 
work on this is ongoing. 
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LITERATURE AND BACKGROUND REVIEW 
 
1.1 Maternal mortality 
 
Maternal mortality is the death of a woman during pregnancy, childbirth or within  the 42 days 
after delivery (Hogan et al., 2010). The Safe Motherhood Initiative was introduced in 1987 as a 
global initiative to raise awareness of the lack of health programmes concerning maternal health 
in developing countries (Hogan et al., 2010). The World Health Organization (WHO) reports that 
830 women die globally due to pregnancy related complications every day, of these deaths 99% 
of them occur in developing countries (WHO, 2018). 
 
Maternal mortality is high amongst women living in sub-Saharan Africa, where 56 % of people 
living with HIV are women  (UNAIDS, 2018). Notably, pregnancy related complications in South 
Africa (SA) are a major public health issue (Moodley et al., 2018). Pregnancy places all women 
at risk for a pregnancy-related event however, some women are at a higher risk of morbidity and 
mortality (Hirshberg and Srinivas, 2017). The main cause of maternal deaths in SA result from 
non-pregnancy related infections such as HIV infection, tuberculosis and pneumonia. Reliable 
data from SA emanating from WHO recommendations for the Safe Motherhood programme 
underscores HIV/AIDS as the most common cause of maternal deaths (Moodley et al., 2010). 
The remaining causes of  maternal deaths are haemorrhage, high blood pressure, unsafe abortions 
and complications from delivery (Say et al., 2014). Additionally, hypertensive disorders are the 
most common medical complication in pregnancy and account for 20.7% of maternal deaths 
within SA (Saving mothers 2014–2016, 2017). 
 
 
1.2 HIV and AIDS in South Africa 
 
HIV infection compromises an individual’s immune system by causing a progressive loss of 
CD4+ T cells (Poulton, 2018). Globally more than 2 million HIV infected women become 
pregnant every year, with the majority residing in sub-Saharan Africa (Moodley et al., 2010). SA 
has a high HIV infection prevalence with an estimated number of 7.52 million infected in 2018 
(Statistics, 2018). Approximately one-fifth of women from SA in their reproductive ages (15-49 
years) are HIV +ve, increasing the risk of mother to child HIV transmission (Dellar et al., 
2015;Statistics, 2018). This form of HIV transmission occurs at 3 stages: 
1) During pregnancy when HIV crosses the placenta.  
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2) During delivery through the contact of vaginal secretions or blood.  
3) During breast-feeding via breastmilk (Poulton, 2018).   
 
 
1.3 Pre-eclampsia 
 
Hypertension is defined as the presence of a chronic elevation of systemic arterial pressure above 
a certain threshold (Khaliq et al., 2018). The number individuals affected by hypertension is 
expected to increase by approximately 560 million people worldwide by the year 2025 (Poulter 
et al., 2015). Hypertensive disorders are responsible for a large amount of pregnancy 
complications in developing countries, such as SA (Hutcheon et al., 2011). There are various 
types of hypertensive disorders however, this study will be looking at pre-eclampsia (PE). 
 
 PE is a systemic syndrome identified by proteinuria, new-onset hypertension and poor placental 
perfusion in pregnant women (Hutcheon et al., 2011). Maternal mortalities as a result of PE are 
estimated at 15-20 % in developing countries (Sibai et al., 2005). The risk of a mother dying due 
to PE are higher in regions such as sub-Saharan Africa in comparison to developed countries 
(Abalos et al., 2013). In SA, PE accounts for 14.8% of all maternal deaths (Saving mothers 2014–
2016, 2017). The diagnostic criteria for PE remains contentious, with angiogenic biomarkers 
remaining a predictor test for the development of PE (Sibai et al., 2005).  
 
1.3.1 Risk factors of pre-eclampsia 
 
Pre-eclampsia has various risk factors, in fact it is considered “the disease of theories” as its 
pathogenesis is varied, not concise and unclear (Trogstad et al., 2011).  Women who are at high 
risk of developing PE include those with pre-existing hypertension, chronic kidney disease and 
women with previous early onset PE (English et al., 2015). Additional risk factors include 
smoking in pregnancy, multiple gestations and also ethnicity; Black women are at a higher risk 
when compared to White women (Trogstad et al., 2011). There are familial factors that contribute 
to PE development, where a family history of PE increases the risk of PE development (Hutcheon 
et al., 2011). Moreover, numerous evidence shows that paternal genes significantly increase the 
risk of PE (Agius et al., 2018). 
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1.3.2 Pathophysiology of pre-eclampsia 
 
For the successful implantation of the placenta, complex interactions occur. Placentation involves  
trophoblast invasion of maternal spiral arteries by trophoblast cells (Gathiram and Moodley, 
2016). The invasion of trophoblasts cells via the decidua  results in the transformation of spiral 
arteries into low-resistance vessels (Trogstad et al., 2011). These trophoblast cells are also 
responsible for cytokine production, communication of maternal immune cells and angiogenesis 
(Trogstad et al., 2011).  A pregnant woman reacts to the foetal trophoblast through a sterile, low-
grade maternal inflammatory response (Ngene and Moodley, 2017).  
 
In pre-eclamptic women, trophoblast invasion is dysregulated  and transformation of the 
myometrial spiral arteries is limited to the decidua during the first trimester of pregnancy (Figure 
1.1) (Trogstad et al., 2011;Salman et al., 2018). The consequence of this is reduced blood flow to 
the placenta leading to poor fetal growth as a result of placental dysfunction (Gathiram and 
Moodley, 2016). The reduced blood flow results in an ishaemic placenta, which  is identified as 
the central hypothesis governing pre-eclamptic pathogenesis (Chaiworapongsa et al., 2014). The 
ischaemic placenta  releases pro-inflammatory factors into maternal circulation and causes 
systemic endothelial dysfunction leading to the clinical manifestations of the disease 
(Chaiworapongsa et al., 2014). The hypoxic micro-environment results in an excess generation 
of reactive oxygen species (ROS) (Trogstad et al., 2011). The accumulation of ROS causes a self 
perpetuating inflammatory response which results in chemical destruction and ultimately tissue 
degradation and cell death (Ngene and Moodley, 2017). The latter contributes to a physiological 
imbalance causing an exaggerated systemic inflammatory response (Pinheiro et al., 2013).  
 
1.3.3 HIV-associated pre-eclampsia 
 
South Africa has one of the largest public anti-retroviral therapy (ART) programmes in the world 
(Malaza et al., 2012). The introduction of highly active antiretroviral therapy (HAART) has 
resulted in an increase in the incidence of  PE (Suy et al., 2006).  However, HIV is responsible 
for the immune suppression of an infected women and PE is associated with an elevated immune 
response; hence a neutralization is expected. However, HAART reconstitutes ones immune 
response, thus increasing PE development (Phoswa et al., 2018). Nonetheless, the relationship 
between HIV infection, HAART and PE needs to be further investigated because of the high 
maternal mortality rate in SA. 
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Figure 1.1: A complex model showing the pathophysiology of PE. In pre-eclamptic women there is 
dysregulation of trophoblast cells invasion, accompanied with oxidative stress. This results in the lack 
of myometrial spiral artery remodelling causing placental dysfunction. The ischaemic placenta 
releases ROS. Moreover, an angiogenic imbalance coupled with ROS results in endothelial 
dysfunction. Leukocyte and endothelial cell activation lead to the maternal clinical manifestations of 
the disease. Adapted from Chaiworapongsa et al. (2014). 
 
 
 
 
 
 
 
 
 
 
       
Spiral artery failure 
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1.4 Angiogenesis in pre-eclampsia 
 
Circulating anti-angiogenic proteins such as soluble fms-like tyrosine kinase-1 (sFlt1) and soluble 
endoglin (sEng) inhibit pro-angiogenic factors [vascular endothelial growth factor (VEGF) and 
placental growth factor (PIGF)] in PE (Karumanchi, 2016). VEGF plays a role in stabilizing 
endothelial cells in mature blood vessels and also maintains the endothelium in the kidney, brain 
and liver; organs severely affected in PE (Wang et al., 2009). PIGF stimulates angiogenesis under 
conditions of ischaemia, inflammation and wound healing (Wang et al., 2009). Literature shows 
that VEGF and transforming growth factor (TGF-β1) play an essential role in maintaining the 
endothelium of the placenta (Karumanchi, 2016). In a normal pregnancy there is vascular 
homeostasis between angiogenic factors, VEGF and TGF-β1 (Gathiram and Moodley, 2016). 
However, in PE excess placental excretion of endogenous anti-angiogenic proteins, sFlt1 and 
sEng inhibit VEGF and TGF-β1 signalling in the vasculature causing endothelial cell dysfunction 
(Khaliq et al., 2018). The pathogenesis of PE involves the presence of an anti-angiogenic state, 
whereby the imbalance of angiogenesis is identified as the most important factor 
(Chaiworapongsa et al., 2014). There have been other proteins with angiogenic activity that have 
been implicated in PE development however, none have been established to have a predictor test 
value early in pregnancy (Maynard and Karumanchi, 2011).  
 
 
1.5 Follistatin 
 
Follistatin (FS) is an extracellular glycoprotein identified as an inhibitor of pituitary follicular 
stimulating hormone (FSH) secretion. It was first isolated from porcine follicular fluid  (Hansen 
and Plomgaard, 2016). The FS protein functions by preventing the ligand-receptor interaction of 
activin, which belongs to the TGF-β superfamily (Flanagan et al., 2009). The extracellular FS 
molecule binds to the activin  homodimer with a high affinity, resulting in the restriction of activin 
bioavailability for the stimulation of FSH secretion (Keutmann et al., 2004). Additionally, FS is 
an important mediator of cell secretion, development and differentiation in numerous body 
systems (Sidis et al., 2001). Furthermore, it can be found in the pituitary, reproductive organs and 
also in the kidney (Blumenfeld and Ritter, 2001).  
 
The distribution of FS occurs among all tissues in which activin is also present (Sidis et al., 2001). 
TGF-β family members, including activin and myostatin bind to type I and type II receptors and 
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lead to type I receptor phosphorylation (Zhang et al., 2018). This receptor then phosphorylates 
the secondary messenger molecule smads, which complexes with a common smad4 (Zhang et al., 
2018). This complex then translocates to the nucleus where it activates gene transcription (Zhang 
et al., 2018). However, in the presence of extracellular FS, the TGF-β superfamily members 
effects are neutralized as a result of  FS binding to them (Figure 1.2) (Zhang et al., 2018). 
 
 
Figure 1.2: Diagram showing the regulation of activin signalling by follistatin. Two FS molecules, 
which bind activin thereby preventing binding of activin to its receptors. This inhibits gene 
transcription. Adapted from Zhang et al. (2018).  
 
1.5.1 Follistatin in pre-eclampsia  
 
Pre-eclamptic symptoms are a result of the ischaemic placenta and studies conducted on FS show 
that it has a role in regeneration after ischaemic injury (Welt et al., 2002).  A rat model with 
arterial damage showed a reduction in histological defects after the infusion of FS, implicating 
FS in repair processes (Welt et al., 2002).  Moreover, circulating levels of FS are not affected by 
a woman’s reproductive tissues, so  FS levels in the serum do not change during a woman’s 
menstrual cycle (Hansen and Plomgaard, 2016). Studies show that the serum concentration of FS 
in small for gestational age infants is higher than in appropriate for gestational age infants 
(Sebastiani et al., 2011). This may be attributed to the role of FS in regulating fat, lean mass and 
muscle growth through its inhibitory effects on activin and myostatin (Anastasilakis et al., 
 
Type 1 receptor 
Follistatin 
Activin 
Type 2 receptor 
Gene transcription 
Gene 
transcription 
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2016).The increase in FS levels could be a compensatory mechanism to regulate the infants’ 
weight. Since we know that PE is associated with a baby’s weight we can assume that FS serum 
levels will be elevated in PE. However, due to oxidative stress occurring in PE there will be a 
decrease in the levels of FS (Zhang et al., 2018). Previous studies conducted on FS have reported 
that in PE, FS functions in the inhibition of PE development via its pro-angiogenic role (Zhang et 
al., 2018).  
 
1.5.2 Follistatin in HIV-associated pre-eclampsia 
 
The FS protein is an important regulator of regulatory T cells, natural killer cells and also dendritic 
cells (Werner and Alzheimer, 2006). An HIV infected woman will have a depletion of CD4+ T 
cells resulting in an impaired cellular immune response (Okoye and Picker, 2013). Activin acts 
as a pro-inflammatory agent in diseases such as PE (Refaat et al., 2014).  FS on the other hand 
plays a role in the inflammatory response by direct inhibition of activin (Miyamoto et al., 2011). 
Additionally, FS plays a role in both innate and humoral immune responses, with evidence 
implicating the protein in immune response to several pathogens including viruses (Werner and 
Alzheimer, 2006).  
 
Since PE is associated with inflammation, there will be an upregulation of FS during inflammation 
(Hedger et al., 2011). This serves to counteract the effect of activin, which acts as a critical 
amplifier of inflammation (Hedger et al., 2011). Additional inflammatory cytokines such as IL1-
β, TNF-α and IFN-γ, also result in the upregulation  of FS to mediate an inflammatory response 
(Hedger et al., 2011). Moreover, activin inhibits endothelial cell proliferation however, FS blocks 
this inhibitory effect because it is strongly expressed by migrating endothelial cells (Gerritsen, 
2008). Literature suggests that FS may be a potential angiogenic biomarker that can counteract 
the development of PE however, it is unclear how FS expression is affected by HIV status in pre-
eclamptic women. 
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1.6 Granulocyte-colony stimulating factor 
 
Granulocyte-colony stimulating factor (G-CSF) is a 19.6 kDa glycoprotein consisting of 4 
antiparallel α helicases. Originally identified in serum as it induced differentiation of the murine 
myelomonocytic leukemic cell line (Schneider et al., 2006). G-CSF is central in the production 
of neutrophils in healthy and diseased states in response to infection (Bendall and Bradstock, 
2014). The prominent source of G-CSF is monocytes but fibroblasts, mesothelial  and endothelial 
cells have been found to also produce G-CSF (Schneider et al., 2006). Various tissues can produce 
G-CSF when stimulated by inflammatory mediators such as lipopolysaccharides (LPS), TNF-α, 
VEGF, macrophages and fibroblasts leading to an immune response (Cai et al., 2017).  
 
In the hematopoietic system, G-CSF drives the generation of neutrophilic granulocytes from 
myeloic precursor cells by its inhibition of apoptosis and induction of differentiation  (Figure 1.3) 
(Schneider et al., 2006). G-CSF serves as a growth factor that promotes the proliferation and 
differentiation of neutrophil progenitors (Basu et al., 2002). Additionally, G-CSF released in the 
blood stream stimulates the mobilization and production of neutrophils within the bone marrow 
(Bendall and Bradstock, 2014). When an infection occurs there is a typical host response to the 
infection, such as increased production of neutrophils (Basu et al., 2002). The locally produced 
G-CSF by tissues, mediates the function of these neutrophils at the infection site (Bendall and 
Bradstock, 2014). 
 
1.6.1 Granulocyte-colony stimulating factor in pre-eclampsia 
 
Studies have shown that the administration of G-CSF to healthy individuals or experimental 
animals result in  an upregulation of  neutrophil levels, 10 to 15 fold greater than normal levels 
(Basu et al., 2002). Neutrophils are responsible for the production of inflammatory cytokines such 
as IL-8 (Pinheiro et al., 2013). These neutrophils infiltrate the vasculature of women with PE and 
provide a chemotactic gradient that attracts more neutrophils (Pinheiro et al., 2013). The 
neutrophils will subsequently infiltrate into the intimal space where they release ROS 
consequently resulting in inflammation (Pinheiro et al., 2013). Endothelial cells monocytes and 
endometrial cells produce G-CSF, which plays an important role in trophoblastic development 
and placental metabolism (Kamath et al., 2017). There is a paucity of information on G-CSF 
serum levels in PE. However a study done by Natori et al. (2002)  showed that G-CSF played a 
role in promoting angiogenesis in an animal model. There is evidence showing G-CSF has a direct 
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stimulatory action on mature endothelial cells, thereby promoting angiogenesis. A study 
conducted by Lee et al. (2005) showed G-CSF directly stimulates endothelial cell migration and 
enhancing angiogenesis-like network formation on Matrix gel culture in vitro. This suggests that 
G-CSF will have a pro-angiogenic effect in PE. 
 
1.6.2 Granulocyte-colony stimulating factor in HIV-associated pre-eclampsia 
 
The G-CSF glycoprotein plays a role in the mediation of neutrophil release in the blood stream 
(Figure 1.3). Additionally, high circulating levels of  G-CSF result in  neutrophils  altering the 
body’s immune system with an upregulation of inflammation (Cai et al., 2017). Furthermore, G-
CSF is also implicated in the increased release of monocytes which counteract the effect of an 
inflammatory response by releasing anti-inflammatory cytokines (Eyles et al., 2006). This anti-
inflammatory role of  G-CSF is important in pregnancy because it temporarily suppresses an 
immune response by its effects on lymphocytes, macrophages and T helper-2 cells (Kamath et 
al., 2017).  In the exaggerated inflammatory milieu of PE, G-CSF would serve to lower the 
immune response. In HIV infected PE, G-CSF elevates levels of CD4+ T cell subset thereby 
inhibiting inflammatory infiltration (Peng, 2017). Nonetheless, there is a paucity of data on G-
CSF levels in HIV-associated PE. It is plausible to hypothesize that G-CSF may be implicated in 
an immunoregulatory and angiogenic role; hence be of diagnostic value for the early detection of 
PE. 
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 ↑Monocyte production 
 ↑Anti-inflammatory cytokine production 
  
 
Figure 1.3: Diagram showing basic cellular activities of G-CSF. G-CSF promotes the release of 
neutrophils from the bone marrow into blood circulation. These neutrophils are involved in 
phagocytosis and the release of monocytes. G-CSF also acts on neutrophil precursors, increasing 
neutrophil production. More importantly, G-CSF increases the activation of endothelial cells. 
Circulating G-CSF plays an important role in an immune response by decreasing T cell reactivity. 
Adapted from Eyles et al. (2006). 
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1.7 Aim: 
 
To establish the role of FS and G-CSF in HIV-associated normotensive pregnancy and PE using 
the Bio-Plex Multiplex Immunoassay. 
 
 
1.8 Objectives: 
 
 To determine the effect of HIV status (HIV +ve vs HIV -ve) on FS and G-CSF serum 
concentrations, irrespective of pregnancy type. 
 To determine the effect of pregnancy type (normotensive vs PE) on FS and G-CSF 
serum concentrations, irrespective of HIV status. 
 To compare FS and G-CSF serum concentrations across the study population (HIV 
+ve normotensive pregnant, HIV -ve, normotensive pregnant, HIV +ve PE and HIV 
-ve PE) 
 To correlate FS and G-CSF serum concentration with maternal age, gestational age, 
parity, blood pressure and maternal weight across the study population. 
 
 
1.9 Study rationale: 
 
Pre-eclampsia and HIV infection are the major causes of maternal mortality and morbidity cases 
in SA. In order to introduce treatment methods, it is important to understand the pathogenesis of 
HIV-associated PE and the role of FS and G-CSF in limiting the effects of both conditions.  
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Abstract 
 
KZN has a high burden of HIV infection and high blood pressure, specifically pre-eclampsia (PE) 
in pregnancy. Follistatin (FS) and granulocyte-colony stimulating factor (G-CSF) are two 
glycoproteins involved in PE pathogenesis. In light of the high maternal mortality and morbidity 
in South Africa (SA), we investigated the expression of FS and G-CSF in the duality of HIV-
associated PE. Serum samples of normotensive and pre-eclamptic women were analysed using 
the Bio-Plex Multiplex Immunoassay. FS expression was significantly reduced in pre-eclamptic 
compared to normotensive pregnancies (649.5±116.8 vs 2354±353.6; p<0.001). However, FS 
expression did not differ between HIV +ve vs HIV –ve groups (1727±291.2 vs 1305±306.7; 
p=0.13). Furthermore, we detected significant FS expression across all study groups. The 
expression of G-CSF was not affected by HIV status i.e., between HIV +ve vs HIV -ve groups 
(14.4±2.3 vs 11.6±0.7, p=0.10) and there was no significant difference between normotensive vs 
pre-eclamptic groups (14.9±2.4 vs 11.3±0.5, p=0.32). G-CSF expression was notably higher in 
HIV +ve normotensive when compared to all study groups. This study demonstrated a 
downregulation of FS and G-CSF expression in PE, compared to normotensive pregnancies. This 
finding may be attributed to oxidative stress and its immunoregulatory role in the 
hyperinflammatory milieu of PE. HIV status had no effect on both analytes, albeit upregulated 
due to immune reconstitution emanating from HAART. Our novel findings suggest that FS and 
G-CSF may have a potential predictor test value in early pregnancy, hence work on this is 
ongoing. 
 
 
Keywords: Pre-eclampsia, HIV, Follistatin, Granulocyte-colony stimulating factor, HAART 
Running title: FS and G-CSF in HIV-associated pre-eclampsia. 
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Introduction 
 
Globally, an estimated 75% of maternal deaths is attributed to haemorrhage, high blood pressure, 
abortions and non-pregnancy related infections such as malaria and human immunodeficiency 
virus (HIV) (1). More than 2 million HIV infected women become pregnant every year, with the 
majority residing in sub-Saharan Africa (2). In South Africa (SA) more than 21.7% of women are 
living with HIV and are at child bearing age (3). 
Pre-eclampsia (PE) is a hypertensive disorder that affects up to 8 % of all pregnancies annually 
(4). In SA, PE accounts for 14.8% of all maternal deaths (44). PE is identified by proteinuria, 
new-onset hypertension and poor placental perfusion in pregnant women (5). Moreover, 
trophoblast invasion is dysregulated and transformation of the spiral arteries is limited to the 
decidua during the first trimester of pregnancy (6). The consequence of this deficient invasion is 
reduced blood flow with subsequent poor foetal growth (7). The reduced blood flow results in an 
ischaemic placenta, which releases pro-inflammatory factors and generates an excess reactive 
oxygen species (ROS) into the maternal circulation (8). The resultant endothelial dysfunction 
contributes to the maternal syndrome, characterised as clinical symptoms of PE (9). Notably, ROS 
accumulation causes a self-perpetuating inflammatory response which causes chemical 
destruction and ultimately tissue degrading and cell death (10).  
Follistatin (FS) is an extracellular glycoprotein which functions by preventing the ligand-receptor 
interaction of activin, which belongs to the transforming growth factor-β (TGF-β) superfamily 
which are essential for regulating cell development and growth (11, 12). FS is also an important 
mediator of cell secretion, development and differentiation in numerous body systems (13). 
Moreover, FS plays an important immunoregulatory role in an inflammatory response (14). It is 
a protagonist in both an innate and humoral immune response, with previous studies implicating 
the protein in an immune response to viruses (15). Furthermore, FS is involved in angiogenesis 
(16).  
Granulocyte-colony stimulating factor (G-CSF) is a 19.6 kDa glycoprotein consisting of 4 
antiparallel α helicases, originally identified in serum as it induced differentiation of the murine 
myelomonocytic leukemic cell line (17). Various tissues can produce G-CSF when stimulated by 
inflammatory mediators such as lipopolysaccharides (LPS), tumour necrosis factor-α (TNF-α), 
vascular endothelial factor (VEGF), macrophages and fibroblasts (18). G-CSF serves as a growth 
factor that promotes the proliferation and differentiation of neutrophil progenitors (19). 
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Additionally, G-CSF released in the blood stream stimulates the mobilization and production of 
neutrophils within the bone marrow (18). Like FS, G-CSF also promotes angiogenesis by 
inducing the proliferation of endothelial cells (20). 
Despite literature demonstrating an upregulation of anti-angiogenic factors in PE, their 
implementation as a predictor test for PE development is poor in low income countries (21, 22). 
South Africa is the epicentre of the global HIV pandemic with a high prevalence of PE (12%), 
hence it is imperative that the association of both conditions is investigated (44). In view of the 
fact that both FS and G-CSF play a role in the pathogenesis of PE, this study will examine their 
expression in women based on pregnancy type (normotensive vs pre-eclamptic) and HIV status 
(HIV +ve vs HIV -ve). 
 
Materials and methods 
 
Ethical approval (BCA 338/17) and regulatory health authority permission were obtained prior to 
recruitment of study participants.  
Study population: Black pregnant women (n=80) were recruited at the Obstetric unit of a large 
regional hospital in Durban, SA and divided into 2 study groups viz., normotensive pregnant and 
pre-eclamptic women. These groups were further stratified by HIV status-into HIV +ve pre-
eclamptic (n= 20), HIV –ve pre-eclamptic (n= 20), HIV +ve normotensive (n= 20) and HIV -ve 
normotensive (n =20). 
Inclusion criteria: PE was defined as systolic blood pressure ≥140mmHg and diastolic blood 
pressure ≥90mmHg and proteinuria occurring after 20 weeks of gestation measured as 300mg of 
protein in a 24-hour urine sample or measured with a dipstick with a value ≥1+, taken 4-6 hours 
apart. The HIV status was determined via a routine rapid test at a large regional hospital and 
CD4+ counts were performed if the woman was HIV +ve. All newly HIV +ve women were 
initiated on combined anti-retroviral therapy (ART). 
Exclusion criteria: Women with chronic diabetes, gestational diabetes, chronic hypertension, 
connective tissue disorder, chronic renal disease, cardiac disease, sickle cell disease, polycystic 
ovarian syndrome, abruption placentae, intrauterine death, unknown HIV status, asthma, pre-
existing seizure disorders, patients with declined participation, unbooked patients and those who 
were unable to provide informed consent were excluded from the study. 
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Sample collection: Following informed consent, venepuncture was used to obtain venous blood 
samples in K3-EDTA tubes. The samples were centrifuged at 1000 rpm for 10 min at 4℃. The 
layers were separated i.e. buffy coat, whole blood and serum and stored in cryovials at -80℃ until 
immunoassay. 
Bio-plex Multiplex immunoassay: The buffy coat (leucocyte suspension) was used to assess 
differences in median fluorescent intensity (MFI) of phosphorylated FS (1:4 dilution) using the 
Bio-Plex® Pro™ Human Cancer Biomarker Panel 1, 16-plex standards (catalogue#171304055M; 
Bio-Rad Inc., South Africa). G-CSF (CSF-3) (1:1 dilution) was assessed using ProcartaPlex 
Human Basic Kit (lot#168095000; Thermo Fisher Scientific., Austria). Both FS and G-CSF 
assays were performed according to the manufacturer’s instructions (23) respectively. The assay 
followed a similar technique to that of a sandwich ELISA, following incubation of antigen 
samples to the study viz, FS and G-CSF with the capture antibody-coupled magnetic beads. 
Biotinylated detection antibodies were added to the reaction, along with reporter conjugate, 
streptavidinphycoerythrin conjugate (SA-PE). After washing, detection of the fluorescence of the 
SA-PE bound to each bead was carried out using the Bio-Plex®MAGPIX™ Multiplex Reader 
(Bio-Rad Laboratories Inc., USA). 
Data analysis: A protocol was generated on the Bio-Plex Manager™ software version 4.1, to 
obtain the data from the multiplex system. The measurement of analyte expression for a given 
bead population in each group was provided as the MFI, which is proportional to the concentration 
of the analyte bound to the reporter. A positive and negative cell lysate control was used for 
qualitative verification of the assay. The data was exported into an Excel spreadsheet for statistical 
analysis. 
Statistical analysis: Data was analysed using GraphPad Prism 5.00 for windows (GraphPad 
Software, San Diego, California USA). Normality test used to check distribution of data 
(parametric or non-parametric). Data is represented as Mean ± Standard Error of Mean. Statistical 
analysis across all groups of the same sample population were based on HIV status and pregnancy 
type, using the One-way ANOVA and the Bonferroni post-hoc multiple comparison test. The 
Mann Whitney’s student t-test was performed for comparison between two groups e.g., HIV +ve 
vs HIV -ve or normotensive vs pre-eclamptic. The level of significance was considered as a 
probability level of p<0.05. 
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Results 
 
Clinical characteristics and patient demographic data 
 
There was no significant difference in maternal age across all study groups (p=0.14). However, 
there was a significant difference in gestational age between HIV-ve normotensive (39.4 ±0.4 
weeks) vs HIV +ve pre-eclamptic (31.1±0.9 weeks) (p<0.0001) and HIV +ve normotensive vs 
HIV-ve pre-eclamptic (p<0001). Additionally, there was no significant difference in parity 
(p=0.25). As expected, a statistical significance was detected for both systolic blood pressure 
(p<0.0001) and diastolic blood pressure (p<0.0001) between the normotensive and pre-eclamptic 
group. There was no significant difference in maternal weight across all study groups (p=0.91). 
 
 
FS expression 
 
HIV status: Regardless of pregnancy type (normotensive vs pre-eclampsia), there was no 
significant difference in FS expression between HIV +ve and HIV-ve groups (1727±291.2 vs 
1305±306.7, p=0.13; Figure 1A). The MFI of FS was upregulated in HIV infection, albeit non-
significantly. 
Pregnancy type: FS expression was significantly downregulated in pre-eclamptic compared to 
normotensive group, irrespective of HIV status (649.5 vs 2354±353.6 ±116.8, p<0.001; Figure 
1B).  
Across all groups: Figure 1C illustrates FS expression across all study groups. There was a 
significant difference in the expression of FS between the HIV -ve normotensive vs HIV +ve pre-
eclamptic group (2105±552.8 vs 802±213.6, p<0.01), HIV +ve normotensive vs HIV +ve pre-
eclamptic group (2603±449.1 vs 802±213.6, p<0.01) and HIV +ve normotensive vs HIV -ve pre-
eclamptic group (2603±449.1 vs 505.1±99.9, p<0.001).  The expression of FS was highest in the 
HIV +ve normotensive group. 
 
 
 
 21 
 
 
G-CSF expression 
 
HIV status: The expression of G-CSF was not affected by HIV status i.e., between HIV +ve vs 
HIV -ve groups (14.4±2.3 vs 11.6±0.7, p=0.10; Figure 2A), irrespective of pregnancy type.  
Pregnancy type: Regardless of HIV status, there was no significant difference in the MFI of G-
CSF between normotensive vs pre-eclamptic groups (14.9±2.4 vs 11.3±0.5, p=0.32; Figure 2B). 
Additionally, G-CSF was downregulated in the pre-eclamptic group. 
Across all groups: Figure 2C illustrates G-CSF expression across all study groups. There was a 
significant difference between HIV -ve normotensive vs HIV +ve normotensive groups (11.6±1.1 
vs 18.2±4.7, p<0.05). The expression of G-CSF was highest in the HIV +ve normotensive group. 
Nonetheless, the expression of G-CSF was similar between the HIV -ve pre-eclamptic vs HIV 
+ve pre-eclamptic group (11.5±0.8 vs 11.1±0.6 p>0.05). 
 
 
Discussion 
 
This study demonstrates a significant downregulation of FS in PE, irrespective of HIV status. 
These findings are similar to previous studies who attributed this decline to the oxidative stress 
occurring in PE (24). Notably, the findings of (25) also supports FS downregulation in the hypoxic 
micro-environment of PE.  In cultured human umbilical vein endothelial cells, activin induces 
ROS production through activating smad2/3 to increase NADPH oxidase 2 (NOX2) activity, 
which causes endothelial dysfunction (26). The presence of activin promotes ROS production and 
exacerbates PE development, while FS inhibits this process by neutralizing activin (24). In 
contrast, FS downregulates NOX2 protein levels to reduce the production of ROS, thus protecting 
endothelial cells (26). Moreover, FS has an angiogenic role and is strongly expressed in migrating 
endothelial cells (27). This migration activity of endothelial cells can be inhibited by activin 
however, FS neutralizes the effect of activin thus promoting angiogenesis (27). Notably, FS 
administration/infusion in a rat model with arterial damage was shown to reduce tissue damage 
and promote the repair process, highlighting the regenerative role of FS in post-ischemic injury 
(28).  PE is associated with oxidative stress, high ROS production and anti-angiogenic imbalance. 
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Hence, the observed downregulation of FS in our pre-eclamptic group compared to the 
normotensive group. 
Based on HIV status, we report no significant difference in FS expression, irrespective of 
pregnancy type. There was however, an upregulatory trend of FS in HIV infection. Both activin 
and FS have immunoregulatory roles in an inflammatory response (14).  In contrast to activin, FS 
has an anti-inflammatory response by direct inhibition of activin (29). The imbalance between 
activin and FS exaggerates the severity of the inflammatory state in diseases such as asthma and 
carcinogenesis (30). The release of activin precedes the release of other inflammatory cytokines, 
therefore the modulation of the activin and FS system is a potential therapeutic target in HIV-
associated PE which has an inflammatory component (30). The non-significant difference in FS 
expression in this study may be attributed to the use of highly active antiretroviral therapy 
(HAART), a standard of care in all HIV infected patients in SA. The disparate immune response 
of PE and HIV infection would indicate a neutralisation. However, the introduction of HAART 
has resulted in an increased incidence of PE in HIV infected woman (31). HAART re-establishes 
immunocompetence thereby, exacerbating the exaggerated immune response of PE (32).  
This study also reports a non-significant difference in the expression of G-CSF between the 
normotensive and pre-eclamptic group, regardless of HIV status; albeit a downregulation in the 
latter group. Endothelial cells, monocytes and endometrial cells produce G-CSF, which plays an 
important role in trophoblast invasion and placental metabolism (33). The downregulation of G-
CSF may be attributed to the deficient trophoblast invasion in PE, with resulting angiogenic 
imbalance (9). Nonetheless, there is a paucity of information on G-CSF serum levels in PE. 
However, G-CSF has a role in promoting angiogenesis in an animal model via a direct stimulatory 
action on mature endothelial cells (20, 34). A study conducted by (35) showed G-CSF directly 
stimulates endothelial cell-like network formation on Matrix gel culture in vitro. In light of the 
latter findings, the downregulation of G-CSF observed in our study is predictable, as PE is an 
anti-angiogenic state (8).  
It is worth mentioning that the administration of G-CSF to healthy individuals or experimental 
animals results in neutrophilia (36). Neutrophils are responsible for the production of 
inflammatory cytokines such as interlukin-8 (37). These neutrophils infiltrate the vasculature of 
women with PE and provide a chemotactic gradient that attracts more neutrophils (38). The 
neutrophils will subsequently infiltrate into the intimal spaces where they release ROS 
consequently resulting in inflammation (38). Moreover, (39) showed that a high dosage of G-CSF 
is associated with an upregulation of inflammation. The unexpected downregulation of G-CSF in 
PE is attributed to the use of HAART, which re-establishes immunocompetence. In pregnancy, 
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G-CSF temporarily suppresses the immune response by its effect on lymphocytes, macrophages 
and T helper-2 cells (33). This immune response suppression is to prevent an exacerbated 
inflammatory response, such as the one observed in PE.  
In our study, there was no significant difference detected in the expression of G-CSF between 
HIV +ve and HIV -ve groups. However, in the HIV +ve group there was an upregulation of G-
CSF expression when compared to the HIV-ve group. The HIV +ve group will have a drop in 
their CD4+ count as a result of the HIV infection (40). However, the upregulation of G-CSF in 
the HIV +ve group is to combat the CD4+ drop by increasing the percentage of CD4+ regulatory 
T cells (41). Moreover, the use of HAART reconstitutes the maternal immune response. This 
suggests that G-CSF upregulation in the HIV +ve group is to elicit its anti-inflammatory 
properties (44). Previous studies show that in vitro, G-CSF decreases lipopolysaccharide-induced 
secretion of pro-inflammatory cytokines by increasing the activity of monocytes (36).  This 
consequently results in the increased release of anti-inflammatory cytokines (43). These anti-
inflammatory cytokines are to combat the duality of HIV and PE with the adverse effects of 
HAART. 
 
Limitations 
 
The study was limited by a small sample size and non-inclusion of other ethnicities. The use of 
HAART may have influenced the expression of our analytes however, further studies are required.  
 
Conclusion 
 
This study demonstrates a downregulation of FS and G-CSF expression in PE, possibly due to 
oxidative stress and the anti-angiogenic micro-environment of PE. In addition, a limitation of the 
study was the small sample size. These novel findings suggest that both FS and G-CSF have 
potential predictor test value for early diagnosis of PE development. HIV status did not influence 
FS and G-CSF expression, this may be attributed to the effects of the HAART regimen adopted 
in SA. It is also plausible to assume that the upregulation of FS and G-CSF expression (albeit 
non-significant) in the HIV +ve group, arises as a result of the immune response in controlling 
viral infection. Further studies will interrogate FS and G-CSF levels across the trimesters of 
pregnancy and introduce a larger sample size. 
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Figure 1: FS expression: (A) based on HIV status; no significance (ns) (B) based on pregnancy type; 
***p<0.001 and (C) across all study groups;**p<0.01 ***p< 0.001. Results are represented as mean 
± SEM. 
HIV-negative HIV-positive
0
1000
2000
3000
4000
1A
HIV Status
F
o
l
l
i
s
t
a
t
i
n
 M
F
I
Normotensive Pre-eclamptic
0
1000
2000
3000
***
1B
Pregnancy type
F
o
l
l
i
s
t
a
t
i
n
 M
F
I
0
1000
2000
3000
4000
5000
HIV-negative normotensive
HIV-positive normotensive
HIV-negative pre-eclamptic
HIV-positive pre-eclamptic
**
***
**
1C
Groups
F
o
ll
is
ta
ti
n
 M
F
I
 30 
 
Graph 2A error bars adjusted. 
  
 
 
Figure 2: G-CSF expression: (A) based on HIV status; no significance (ns) (B) based on pregnancy 
type; no significance (ns) and (C) across all study groups; *p<0.05. Results are represented mean ± 
SEM. 
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Table 1: Clinical demographic results. Mean ± SEM are represented; One-way ANOVA 
and the Bonferroni post hoc multiple comparison test was used for statistical analysis, n= 80 
 
 
 
 
 
 
 
  
 
HIV –ve 
normotensive 
n=20 
HIV +ve 
normotensive 
n=20 
HIV –ve 
pre-eclamptic 
n=20 
HIV +ve 
pre-eclamptic 
n=20 
p-value 
Maternal 
Age 
(years) 
25 ± 1 29 ± 1 26 ± 2 29 ± 6 p=0.14 
Gestational 
Age 
(weeks) 
39 ± 0.4 38.5 ± 0.5 33 ± 1 31 ± 1 p<0.0001 
Parity 1 ± 0.3 1.5 ± 0.2 1 ± 0.2 1.3 ± 0.2 p=0.25 
Systolic BP 
(mmHg) 
120 ± 2 114.6 ± 3 159 ± 4 164 ± 3 p<0.0001 
Diastolic BP 
(mmHg) 
67 ± 2 67.4 ± 2.0 104.4 ± 2 107 ± 2 p<0.0001 
Maternal 
Weight (kg) 
77 ± 3 76 ± 4 77 ± 5 77 ± 6 p=0.91 
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Introduction: KwaZulu-Natal has a high burden of HIV infection and high blood pressure, 
specifically pre-eclampsia (PE) in pregnancy. Follistatin (FS) is an extracellular 
glycoprotein antagonist of the ligand receptor, Activin-A, involved in PE pathogenesis. 
In light of the high maternal mortality and morbidity in SA, we investigated the 
expression of FS in the duality of HIV-associated PE.  
Method: Serum samples of normotensive and pre-eclamptic women stratified by HIV 
status were collected from a large regional hospital in Durban, and their FS expression 
was analysed using the Bio-Plex Multiplex Immunoassay.  
Results: Irrespective of HIV status, FS expression was significantly reduced in pre-
eclamptic compared to normotensive pregnancies (649.5±116.8 vs 2354±353.6; 
p<0.001). However, FS expression did not differ between HIV +ve vs HIV –ve groups 
(1727±291.2 vs 1305±306.7; p=0.13) - regardless of pregnancy type. Furthermore, we 
detected significant FS expression across all study groups (p>0.05).  
Conclusion: This study demonstrates a downregulation of FS expression in PE, possibly 
due to oxidative stress and its immunoregulatory role in the hyperinflammatory milieu of 
PE. Moreover, the fact that FS did not vary by HIV status may be attributed to the effects 
of HAART regimen adopted in SA. It is also plausible to assume that the upregulation of 
FS expression (albeit non-significant) in HIV +ve patients, arises as a result of the 
immune response in controlling viral infection. Our novel findings suggest that FS may 
have a potential predicator test value early in pregnancy, hence work on this is ongoing. 
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SYNTHESIS 
 
Maternal mortality within the African continent is high, with sub-Saharan Africa accounting for 
85 % of the maternal mortality rate (Amzat, 2015). Whilst pregnancy places most women at a 
higher risk for a pregnancy-related event, some women are at higher risk of mortality than others 
(Hirshberg and Srinivas, 2017). More than 75 % of pregnancy related deaths are caused by 
hypertension and HIV, so clarification of the interaction in the duality of these conditions is 
imperative (Say et al., 2014). There are more than 2 million pregnancies in HIV infected women 
worldwide, with the majority occurring within sub-Saharan Africa (Moodley et al., 2010). In SA, 
one-fifth of women in their reproductive ages are HIV +ve (Statistics, 2018). Furthermore, 
hypertensive disorders such as PE contribute directly to maternal deaths occurring in SA 
(Moodley, 2010). Notably, PE accounts for 14.8% of all maternal deaths occurring within SA 
(Saving mothers 2014–2016, 2017).  
 
Globally, PE affects 5-7% of pregnancies, with immunological and genetic factors implicated in 
its pathogenesis (Salman et al., 2018). A defective trophoblast and the non-physiological 
conversion of myometrial spiral arteries contributes to placental ischaemia and the ensuing 
hypoxia which characterizes PE (Chaiworapongsa et al., 2014). Moreover, an angiogenic 
imbalance in favour of elevated anti-angiogenic factors such as sFlt1 and sEng exist in PE together 
with a concomitant downregulation of pro-angiogenic factors [PIGF and VEGF] (Maynard and 
Karumanchi, 2011;Ngene and Moodley, 2017).  
 
This study demonstrates a downregulation of FS in PE compared to the normotensive pregnant 
groups, irrespective of HIV status. These findings are corroborated by Zhang et al. (2018) who 
attributed the decline of FS to the high oxidative stressed micro-environment of PE. Similarly a 
longitudinal analysis also showed that serum FS levels are lower in women with PE compared to 
normotensive pregnant women (Garces et al., 2015). FS is  a glycosylated single-chain protein 
observed in the inhibition of  FSH secretion (Kelaini et al., 2018). The local role of FS is to 
neutralize the effect of activin by binding to its receptor thereby restricting activin bioavailability 
for stimulation of FSH  (Keutmann et al., 2004). In PE, serum activin is significantly higher 
compared to normotensive pregnant women (Yu et al., 2011). Moreover, in PE- activin induces 
oxidative stress via the activation of smad2/3 promoting the release of NADPH oxidase 2 
(NOX2), causing a hypoxic environment that results in FS downregulation (Zhang et al., 2018). 
Furthermore, FS plays a role in tissue restoration and is involved in endothelial cell 
differentiation, including angiogenesis (Kelaini et al., 2018). It is well established that an 
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angiogenic disproportion in favour of anti-vs pro-angiogenic state prevails in PE (Gathiram and 
Moodley, 2016). Since FS is a pro-angiogenic molecule, the downregulation of FS in PE is 
plausible , in view of the decreased angiogenesis (Turcotte et al., 2017). Additionally, our findings 
are supported by Charkiewicz et al. (2018) who reported that pro-angiogenic factors (VEGF and 
PIGF) are downregulated, with a concurrent significant decline in FS expression in women with 
PE. 
 
In contrast, a study conducted by Founds et al. (2015) described an upregulation of follistatin-
like 3 (FSL3) over the course of pregnancy in women who subsequently developed PE. This was 
attributed to the higher insulin resistance in PE and/or to the effects of hypoxia. Results are 
contradictory in that enhanced serum FS levels have been reported in PE compared to 
normotensive pregnant women (Keelan et al., 2002). However, D'Antona et al. (2000) reported 
the inverse.  
 
This current study reports a non-significant difference albeit, an upwards trend in FS between the 
HIV +ve compared to the HIV –ve group, irrespective of pregnancy type. In HIV infection there 
is a loss of CD4+ cells and the suppression of the immune system (Poulton, 2018). Klein et al. 
(1996) showed that FS levels increased in sheep after the administration of  LPS , illustrating the 
role of FS in the acute phase of an inflammatory response .Moreover, FS administration to mice 
reduces the levels of LPS, suggesting that FS has an anti-inflammatory effect (Hansen and 
Plomgaard, 2016).  Notably, the anti-inflammatory effect of FS has been shown in patients with 
sepsis (Phillips et al., 2001).  
 
Moreover, inflammation related to hypoxia induces activin, which increases FSL3 transcription 
via the smad proteins (Founds et al., 2015). Activin is expressed within inflammatory cells, 
promoting an inflammatory response (Monsuur et al., 2018). The latter studies suggest that in an 
HIV infection, FS expression would be increased to neutralize the effects of activin. Confounding 
our results, is the fact that a standard of care practice in SA is HAART. This standard of care 
induces immune reconstitution in HIV infected pre-eclamptic women (Phoswa et al., 2018). This 
implies that serum levels of activin would rise to elicit a systemic inflammatory response that is 
exacerbated in PE. The interaction of activin with smad proteins and the stimulation of nitric 
oxide metabolites is inhibited by the upregulation of FS (Phillips et al., 2001). Therefore, we 
hypothesize that the FS upregulation in HIV +ve pre-eclamptic woman is a compensatory 
mechanism to neutralize the effects of activin, a release stimulated by the immune reconstitution 
effect of HAART.   
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In our study, there was no significant difference in the expression of G-CSF between the pre-
eclamptic vs normotensive group, irrespective of HIV status. However, there was an observed 
down regulatory trend of G-CSF in PE. G-CSF is a glycoprotein that induces the differentiation 
of myelomocytic leukemic cell line (Schneider et al., 2006). The G-CSF receptor is a single 
homodimer receptor which mediates the effects of G-CSF (Bendall and Bradstock, 2014). This 
receptor signals via STAT3, STAT5 and the MAPK cell signalling pathways (Hamilton et al., 
2016). It is plausible that STAT3 is downregulated in HIV infection negatively influencing 
dendritic cell function, thereby interfering with the mechanism that links innate and adaptive 
immunity. 
 
Literature suggests that G-CSF promotes angiogenesis inducing the proliferation of endothelial 
cells (Kohlstedt et al., 2018). Lee et al. (2005), showed that recombinant G-CSF when 
administrated in low doses effectively augments ischaemia, inducing angiogenesis in vivo. G-CSF 
and VEGF  mobilize endothelial cells from the bone marrow into peripheral circulation and 
promote angiogenesis (Okazaki et al., 2006). In PE, the angiogenic  imbalance in favour of anti-
angiogenic factors vs pro-angiogenic factors (G-CSF) results in endothelial dysfunction (Kalumba 
et al., 2013).  
 
Notably, endothelial cells produce G-CSF, since PE is characterized by endothelial dysfunction 
there will be a downregulation in G-CSF production. This was observed in our study as G-CSF 
was downregulated in the pre-eclamptic group. The production of G-CSF can be induced in vitro  
by TNF-α , IL-1 and bacterial LPS (Daniels and Lewin, 2008). These cytokines are present in 
pre-eclamptic women as a result of oxidative stress eventuating in an increase in G-CSF. The G-
CSF downregulation noted in our study could be attributed to HAART as it reconstitutes the 
maternal immune response. 
 
Furthermore, G-CSF expression in our study were similar between HIV +ve vs HIV –ve groups, 
regardless of pregnancy type. G-CSF plays an important role in the mediation of neutrophil 
release in the blood stream, with neutropenia being associated with an upregulation of 
inflammation (Cai et al., 2017). The presence of G-CSF in the blood stream alters the body’s 
immune system, eliciting an immune response to an infection (Basu et al., 2002). Studies have 
highlighted the beneficial effects of G-CSF after it has been administrated in different 
inflammatory conditions (Jeannin et al., 2018). A study conducted by Martins et al. (2010) 
showed that G-CSF has anti-inflammatory properties in vitro and in vivo. In addition, Boneberg 
et al. (2000) showed that in vitro, G-CSF decreases LPS-induced secretion of pro-inflammatory 
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cytokines by increasing mobilization of human monocytes. This suggests that G-CSF has an anti-
inflammatory role by increasing the activation of monocytes, which release anti-inflammatory 
cytokines (Eyles et al., 2006). Notably, in mice G-CSF mobilizes CD34+ progenitors which 
favour T-regulatory cell expansion, protecting the mice from developing type 1 diabetes (Kared 
et al., 2005). 
 
Our study demonstrated that G-CSF has an upregulatory trend in the HIV +ve group compared to 
the HIV –ve group. Since HIV infection is characterized by the drop in an HIV infected 
individuals CD4+ count, mice who were administrated with G-CSF showed an increased 
percentage of CD4+ regulatory T cells (Peng, 2017;Poulton, 2018). Hence in HIV infection, the 
compensatory action of G-CSF would be to promote an immune response. Nonetheless, HAART 
establishes an individual’s immune response thus, the upregulation of G-CSF in HIV infection is 
to mobilize CD4+ cells. 
 
In conclusion, this study reports the downregulation of FS and G-CSF in PE compared to 
normotensive pregnancies reflecting the anti-angiogenic state of PE. Both FS and G-CSF were 
upregulated albeit non-significantly in HIV infection, due to their immunoregulatory role in both 
innate and adaptive response. However, HAART may have affected analyte expression due to 
immune reconstitution in HIV infection further exacerbating the immune response of PE. 
 
Future studies will include a larger sample size, stratification of the PE group by gestational age 
and the consideration of the duration of HAART. 
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APPENDICE 2: Follistatin standard curve 
 
 
APPENDICE 3: G-CSF standard curve 
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